Litcius/Paper detail

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial

David Cella, Robert J. Motzer, Cristina Suárez, Steven I. Blum, Flavia Ejzykowicz, Melissa Hamilton, Joel Wallace, Burçin Şimşek, Joshua Zhang, Cristina Ivanescu, Andrea B. Apolo, Toni K. Choueiri

2022The Lancet Oncology86 citationsDOIOpen Access PDF

Topics & Concepts

CabozantinibSunitinibNivolumabMedicineRenal cell carcinomaInternal medicineOpen labelOncologyUrologyRandomized controlled trialImmunotherapyCancerRenal cell carcinoma treatmentCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis